Population Pharmacokinetics of Metoclopramide in Infants, Children, and Adolescents.

Publication Type
Journal Article
Year of Publication
Ge, Shufan; Mendley, Susan R; Gerhart, Jacqueline G; Melloni, Chiara; Hornik, Christoph P; Sullivan, Janice E; Atz, Andrew; Delmore, Paula; Tremoulet, Adriana; Harper, Barrie; Payne, Elizabeth; Lin, Susan; Erinjeri, Jinson; Cohen-Wolkowiez, Michael; Gonzalez, Daniel; Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee
Clin Transl Sci
Date Published
2020 Apr 23
Adolescents; children; infants; Metoclopramide; Pharmacokinetics; Population

Metoclopramide is commonly used for gastroesphageal reflux. The aims of the present study were to develop a pediatric population pharmacokinetic (PopPK) model, which was applied to simulate the metoclopramide exposure following dosing used in clinical practice. Opportunistic pharmacokinetic (PK) data were collected from pediatric patients receiving enteral or parenteral metoclopramide per standard of care and these data were simultaneously fitted using NONMEM®. Allometric scaling with body weight was included a priori in the model. Using the final model, the steady-state maximum concentrations (C ) and the area under the metoclopramide plasma concentration-time curve at steady state (AUC ) were simulated following 0.1 or 0.15 mg/kg orally every 6 hours in virtual patients, and compared with previously reported ranges associated with toxicity or the efficacy for gastroesophageal reflux in infants. A two-compartment model with first-order absorption best characterized 87 concentration measurements from 50 patients (median [range] postnatal age of 8.89 years [0.01 to 19.13]). There were 20 infants (≤2 years), 9 children (2 years< age ≤12 years) and 21 adolescents (>12 years). Body weight was the only covariate included in the final model. For >75% of virtual patients, simulated C and AUC estimates were within the range associated with efficacy for gastroesophageal reflux in infants; however, slightly lower exposures were predicted in virtual patients <2 years. Our study suggests that a metoclopramide enteral dose of 0.1 mg/kg every 6 hours, which was previously recommended for pediatric patients, results in simulated exposure generally within suggested ranges for the treatment of gastroesophageal reflux.